Physician profile
Angela Boldo
NPI 1407054638
$2,989.30
in general payments reported to CMS, 2019-2025
32 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $446 · 2021: $346 · 2022: $592 · 2023: $271 · 2024: $409 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $588.35 | 2019-2025 | Evenity, Prolia |
| Ibsa Pharma INC. | $317.97 | 2019-2022 | |
| Abbvie INC. | $236.56 | 2019-2024 | Synthroid |
| Lilly USA, LLC | $167.84 | 2020-2025 | Mounjaro, Baqsimi, Jardiance |
| Alexion Pharmaceuticals, INC. | $167.57 | 2020-2025 | Strensiq |
| Horizon Therapeutics Plc | $155.66 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $147.94 | 2019-2024 | Unithroid |
| Eisai INC. | $146.64 | 2022 | |
| Novo Nordisk INC | $115.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $101.66 | 2019-2023 | Tymlos |
| Xeris Pharmaceuticals, INC. | $82.74 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Shire North American Group INC | $73.27 | 2019 | |
| Insulet Corporation | $68.96 | 2024-2025 | Omnipod |
| Dexcom, INC. | $63.14 | 2024-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $58.47 | 2024-2025 | Isturisa, Signifor Lar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $54.50 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $54.44 | 2025 | Yorvipath |
| Almatica Pharma LLC | $51.44 | 2024-2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $47.80 | 2021-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $29.54 | 2023 | |
| Corcept Therapeutics | $28.01 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $26.06 | 2024 | |
| Kyowa Kirin, INC. | $25.65 | 2024 | Crysvita |
| Sandoz INC. | $25.21 | 2025 | Jubbonti |
| Averitas Pharma INC. | $21.68 | 2023 | Qutenza |
| Abbott Laboratories | $21.14 | 2024 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $21.07 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2023 | Jardiance |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Antares Pharma, INC. | $17.83 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $17.55 | 2025 | |
| Alvogen INC | $17.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Boldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.